Related posters
(Anaveon) ANV700 is a novel proximity-activated IL-21 receptor agonist designed to selectively reinvigorate tumor-reactive PD-1 expressing T cells
Efficacy assessment with hPD-1
November 21, 2024
Abstract
Background
Selective delivery of IL-21 to PD-1+ cells through a Proximity-Activated Cytokine (PAC)IL-21 has the potential to increase the cytotoxicity and maintain survival of tumor reactive CD8+ T cells in chronic antigen exposure settings, such as cancer. Clinical studies with recombinant IL-21 showed promising therapeutic benefit, which was limited by dose-limiting toxicity and immunosuppressive effects on antigen-presenting cells. ANV700 addresses these limitations by targeting a novel proximity-activated IL-21 specifically to PD-1-expressing cells. This approach aims to reinvigorate tumor-specific T cells while minimizing off-target effects.
Scientific excellence
From model design to experimental results
Tailor-made solutions adapted to scientific questions
Robust validation data on catalog models
Comprehensive dataset package
Generated with biopharma partners and in-house
Customer care
Scientific follow-up and advice along the project
Collaborative approach for problem solving and development of innovative models
Easy and fast access to models
Breeding facilities in US and Europe
Certified health status from professional breeders